News
NRG receives £2.68m funding boost for neurodegenerative disorders
Neuroscience company NRG Therapeutics has announced that it has received a Biomedical Catalyst award. The £2.68m package will fund the pre-clinical development of its novel small molecule disease-modifying medicines for treating Parkinson’s disease, motor neurone disease (MND) and other debilitating neurodegenerative disorders.